NASDAQ:LTRN Lantern Pharma (LTRN) Stock Price, News & Analysis $2.94 -0.14 (-4.55%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Lantern Pharma Stock (NASDAQ:LTRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lantern Pharma alerts:Sign Up Key Stats Today's Range$2.90▼$3.1950-Day Range$2.94▼$4.0752-Week Range$2.90▼$11.99Volume71,698 shsAverage Volume47,499 shsMarket Capitalization$31.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Read More… Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Lantern Pharma Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks22nd Percentile Overall ScoreLTRN MarketRank™: Lantern Pharma scored higher than 22% of companies evaluated by MarketBeat, and ranked 859th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Lantern Pharma.Read more about Lantern Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lantern Pharma are expected to grow in the coming year, from ($1.90) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantern Pharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantern Pharma is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantern Pharma has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lantern Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.06% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 6.39%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantern Pharma does not currently pay a dividend.Dividend GrowthLantern Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.06% of the float of Lantern Pharma has been sold short.Short Interest Ratio / Days to CoverLantern Pharma has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantern Pharma has recently decreased by 6.39%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.00 News SentimentLantern Pharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lantern Pharma this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantern Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.31% of the stock of Lantern Pharma is held by insiders.Percentage Held by InstitutionsOnly 28.62% of the stock of Lantern Pharma is held by institutions.Read more about Lantern Pharma's insider trading history. Receive LTRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LTRN Stock News HeadlinesLantern Pharma doses first patient in LP-300 trial expansion cohortNovember 20 at 5:57 PM | markets.businessinsider.comLTRN: Pediatric Rare Cancer in FocusNovember 12, 2024 | finance.yahoo.comNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.November 21, 2024 | Darwin (Ad)Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comLantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...November 9, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLantern Pharma Advances AI-Driven Cancer TherapiesNovember 8, 2024 | markets.businessinsider.comLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 7, 2024 | businesswire.comSee More Headlines LTRN Stock Analysis - Frequently Asked Questions How have LTRN shares performed this year? Lantern Pharma's stock was trading at $4.28 at the start of the year. Since then, LTRN shares have decreased by 31.3% and is now trading at $2.94. View the best growth stocks for 2024 here. How were Lantern Pharma's earnings last quarter? Lantern Pharma Inc. (NASDAQ:LTRN) issued its earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.55) by $0.09. When did Lantern Pharma IPO? Lantern Pharma (LTRN) raised $26 million in an initial public offering on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers. Who are Lantern Pharma's major shareholders? Lantern Pharma's top institutional investors include Westside Investment Management Inc. (0.28%). Insiders that own company stock include Leslie W Kreis and Aaron GL Fletcher. View institutional ownership trends. How do I buy shares of Lantern Pharma? Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lantern Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO). Company Calendar Last Earnings8/08/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/17/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LTRN CUSIPN/A CIK1763950 Webwww.lanternpharma.com Phone972-277-1136FaxN/AEmployees20Year Founded2013Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.91% Return on Assets-51.17% Debt Debt-to-Equity RatioN/A Current Ratio8.31 Quick Ratio8.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.76 per share Price / Book0.78Miscellaneous Outstanding Shares10,785,000Free Float9,997,000Market Cap$31.71 million OptionableOptionable Beta1.58 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:LTRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.